Good evening :)
$
₹
United Therapeutics Corporation

United Therapeutics Corporation

UTHR

NASDAQ
Asset Logo

United Therapeutics Corporation

UTHR

NASDAQ
$594.762.25% (-13.72)
$
₹
$594.762.25% (-13.72)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Drug Manufacturers - Specialty & Generic

Large Cap

With a market cap of $25.8B the stock is ranked 541

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

21.53
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

3.99
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$27.92
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

2.22
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

41.56%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 15 analysts reports

Buy
11 analysts
Hold
3 analysts
Sell
1 analyst

Price Upside

+10.26%

Earnings Growth

-4.57%

Rev. Growth

-0.14%

See Detailed Forecast

Company Profile

Company Profile

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
49.14
49.14
1Y Return
32.47%
32.47%
Buy Reco %
79.31
79.31
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
28.64
28.64
1Y Return
56.57%
56.57%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
36.15%
36.15%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
35.59
35.59
1Y Return
30.2%
30.2%
Buy Reco %
81.25
81.25
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
21.51
21.51
1Y Return
48.38%
48.38%
Buy Reco %
67.85
67.85
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Lower price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 10.26% growth, versus a trailing 3-year CAGR of 38.67%.

2026
Current$608.49Baseline
Analyst Target - 1 year
Target$670.93+10.26%

All values in $

202220232024202520262027$332.93$467.96$602.99Target+10.26%
2026
Current$608.49Baseline
Analyst Target - 1 year
Target$670.93+10.26%

All values in $

Revenue Forecast

Revenue Forecast

Lower revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies -0.14% growth, versus a trailing 3-year CAGR of 18.02%.

2025
Current$3.18Baseline
Forecast for Dec 2026
High$3.43+7.94%
Average$3.17-0.14%
Low$3.04-4.26%

All values in $ Billion

2021202220232024202520261.681.932.322.873.18Low-4.26%Average-0.14%High+7.94%
2025
Current$3.18Baseline
Forecast for Dec 2026
High$3.43+7.94%
Average$3.17-0.14%
Low$3.04-4.26%

All values in $ Billion

Earnings Per Share Forecast

Earnings Per Share Forecast

Lower earnings growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies -4.57% growth, versus a trailing 3-year CAGR of 20.19%.

2025
Current$27.9Baseline
Forecast for Dec 2026
High$30.81+10.43%
Average$26.63-4.57%
Low$22.65-18.8%

All values in $

20212022202320242025202613.3516.0719.8425.2827.9Low-18.8%Average-4.57%High+10.43%
2025
Current$27.9Baseline
Forecast for Dec 2026
High$30.81+10.43%
Average$26.63-4.57%
Low$22.65-18.8%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

790.2
364.3
781.5
274.9
783.3
333
832.5
258.6
Q4 2025
Q1 2026
Q2 2026
Q3 2026
Revenue
Net Income
Financial YearQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Total Revenue714.9748.9735.9794.4798.6799.5790.2781.5783.3832.5
Net Income278.1309.1301.3322.2309.5338.7364.3274.9333258.6
Net Profit Margin38.90%41.27%40.94%40.55%38.75%42.36%46.10%35.17%42.51%31.06%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDrug Manufacturers - Specialty & Generic

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
United Therapeutics Corporation 21.533.992.22
AbbVie Inc49.1450.450.58
Amgen Inc28.6421.552.77
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare UTHR with any stock or ETF
Compare UTHR with any stock or ETF
Comparing from
UTHR
ABBV
AMGN
Loading...

Frequently asked questions

  1. United Therapeutics Corporation (UTHR) share price today is $594.76 as of November 5, 2026 at 8:22 PM IST. The stock touched a day high of $601.24 and a day low of $594.05.

  2. United Therapeutics Corporation stock trades on NASDAQ under the ticker symbol UTHR.

  3. United Therapeutics Corporation's market capitalization is $25.79B as of November 5, 2026 at 8:22 PM IST.

  4. United Therapeutics Corporation's price-to-earnings (P/E) ratio is 21.53 as of November 5, 2026.

  5. United Therapeutics Corporation's price-to-book (P/B) ratio is 3.99 as of November 5, 2026.

  6. Yes, You can buy United Therapeutics Corporation shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy United Therapeutics Corporation shares in three steps: 1. Search United Therapeutics Corporation on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since United Therapeutics Corporation trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in United Therapeutics Corporation (UTHR) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.0168 shares at the current price of $594.76.

Loading...